Alivus Life Sciences Ltd acquires 65.01% of IQGEN-X Pharma, making it a subsidiary
- Acquired 7,36,096 equity shares under the share purchase agreement.
- IQGEN-X became a subsidiary effective November 11, 2026; the remaining share capital is to be acquired in due course.
- The agreement, announced August 18, 2026, covered a proposed 76% stake.
